We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Newly Identified Biomarker Indicates Risk of Breast Cancer Bone Metastasis

By LabMedica International staff writers
Posted on 28 Sep 2015
Cancer researchers have identified a gene that is critically linked to the ability of some breast cancer tumors to metastasize to the bone and which may be developed into a biomarker to identify patients at risk for this development.

There are currently no biomarkers for early breast cancer patient populations at risk of bone metastasis, which occurs in about 15%–20% of patients with estrogen-receptor-positive breast tumors. More...
These tumors tend to metastasize to the bone, and represent 80% of all breast cancers.

Investigators at the Institute for Research in Biomedicine (Barcelona, Spain) analyzed more than 900 clinical samples of primary breast tumors while looking for genetic variations that favored bone metastasis.

They reported in the September 15, 2015, online edition of the Journal of the National Cancer Institute that patients with tumors in which the MAF (v-maf avian musculoaponeurotic fibrosarcoma oncogene homolog) gene was altered had a risk of metastasis to the bone that was 14 times higher than in those patients in which the gene was unaltered.

"This gene reliably predicts metastasis to the bone. Studying whether it is highly expressed in breast cancer patients to determine whether this also happens in a clinical setting is an important next step. It could improve the quality of life of these patients and the way clinicians manage their cancer. And this is exactly what we are doing," said senior author Dr. Roger Gomis, oncology group leader at the Institute for Research in Biomedicine.

The findings obtained in this study have led to the creation of the company Inbiomotion (Barcelona, Spain), which has developed the tools necessary to begin clinical trials. An initial clinical trial will validate the use of the marker in some 3,300 patients.

Related Links:

Institute for Research in Biomedicine
Inbiomotion




New
Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
Portable Electronic Pipette
Mini 96
New
Gold Member
Automatic Hematology Analyzer
DH-800 Series
New
Gel Cards
DG Gel Cards
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Pathology

view channel
Image: Erythrocyte Sedimentation Rate Sample Stability (Photo courtesy of ALCOR Scientific)

ESR Testing Breakthrough Extends Blood Sample Stability from 4 to 28 Hours

Erythrocyte sedimentation rate (ESR) is one of the most widely ordered blood tests worldwide, helping clinicians detect and monitor infections, autoimmune conditions, cancers, and other diseases.... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.